UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2024.
Commission File Number: 001-40065
IM Cannabis Corp.
(Exact Name of Registrant as Specified in Charter)
Kibbutz Glil Yam, Central District, Israel 4690500
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Note: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Note: Regulation S-T Rule
101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not
required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
IM CANNABIS CORP.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
Date:
|
August 6, 2024
|
By:
|
/s/ Oren Shuster
|
|
|
|
Name:
|
Oren Shuster
|
|
|
|
Title:
|
Chief Executive Officer and Director
|
EXHIBIT INDEX
FORM 7
MONTHLY PROGRESS REPORT
Name of Listed Issuer: IM Cannabis Corp. (the “Issuer” or “IMC” or the "Company")
Trading Symbol: IMCC
Number of Outstanding Listed Securities as of 7/31/2024:
2,232,359 Common Shares
Date: August 6, 2024
Report on Business
| 1. |
Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose
this fact.
|
|
• |
On July 1st, 2024, IMC Holdings entered into a short-term loan agreement with a non-financial institute in the amount of NIS 3,000 thousand
(approximately $1,113). Such loan bear interest at an annual rate of 12% and mature 62 days from the date of signing the loan agreement.
|
|
• |
On July 5, 2024, the Company announced that the board of directors of the Company (the "Board") has approved a consolidation of its issued and
outstanding common shares ("Common Shares") on the basis of one post-consolidated Common Share for every six pre-consolidated Common Shares (the "Consolidation"). The Board has set July 12, 2024 as the effective date of the Consolidation and
anticipates the Common Shares to trade on a post-consolidated basis effective July 12, 2024, subject to final confirmation from the Canadian Securities Exchange (the "CSE") and Nasdaq Stock Market LLC (the "NASDAQ"). The exercise price and/or
conversion price and number of Common Shares issuable under any of the Company's outstanding convertible securities were proportionately adjusted in connection with the Consolidation.
|
Shareholders of record as of the effective date received a letter of transmittal from
Computershare Investor Services Inc., the Company's registrar and transfer agent for the Common Shares, providing instructions for the exchange of their Common Shares as soon as practicable following the effective date. Registered shareholders may
also obtain a copy of the letter of transmittal by accessing the Company's SEDAR+ profile at www.sedarplus.ca. Until surrendered, each share certificate or direct registration system statement representing pre-consolidated Common Shares will
represent the number of whole post-consolidated Common Shares to which the holder is entitled as a result of the Consolidation. No action was required by beneficial holders to receive post-consolidation Common Shares in connection with the
Consolidation. Beneficial holders who hold their Common Shares through intermediaries (e.g., a broker, bank, trust company investment dealer or other financial institution) and who have questions regarding how the Consolidation will be processed
should contact their intermediaries with respect to the Consolidation.
|
• |
On July 12, 2024, the Company announced that, further to its press release dated July 5, 2024, effective July 12, 2024, the Company's common shares
("Common Shares") are trading on the CSE and NASDAQ on a 6:1 post-consolidated basis (the "Consolidation"). The Company's trading symbol remains "IMCC" on both the CSE and NASDAQ. The Company's new CUSIP and ISIN numbers are 44969Q406 and
CA44969Q4060, respectively. After giving effect to the Consolidation, the Common Shares were reduced from 13,394,136 to 2,232,357 Common Shares. No fractional Common Shares were issued in connection with the Consolidation. Instead, all
fractional Common Shares equal to or greater than one-half resulting from the Consolidation were rounded to the next whole number, otherwise, the fractional Common Share were cancelled. The exercise price and/or conversion price and number of
Common Shares issuable under any of the Company's outstanding convertible securities were proportionately adjusted in connection with the Consolidation. Computershare Investor Services Inc., the Company's registrar and transfer agent for the
Common Shares, has mailed letters of transmittal to registered shareholders of record as of July 12, 2024 providing instructions for the exchange of their Common Shares as soon as practicable following the effective date. Registered
shareholders may also obtain a copy of the letter of transmittal by accessing the Company's SEDAR+ profile at www.sedarplus.ca. Until surrendered, each Common Share certificate or direct registration system statement representing
pre-consolidated Common Shares will represent the number of whole post-consolidated Common Shares to which the holder is entitled as a result of the Consolidation. No action is required by beneficial holders to receive post-consolidation
Common Shares in connection with the Consolidation. Beneficial holders who hold their Common Shares through intermediaries (e.g., a broker, bank, trust company investment dealer or other financial institution) and who have questions regarding
how the Consolidation will be processed should contact their intermediaries with respect to the Consolidation.
|
*After giving effect to the Consolidation, the Common Shares were reduced from 13,394,136 to
2,232,359 (after rounding fractional Common Shares).
|
• |
On July 29, 2024, announced that on July 26, 2024, it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the
Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement"). IMC is now in compliance with all applicable listing standards and will
continue to be listed and traded on the NASDAQ Stock Market.
|
As previously announced, the Company was notified by Nasdaq on August 1, 2023, that it was not
in compliance with the Minimum Bid Price of $1.00 per share for 30 consecutive business days as required by the Listing Rules of Nasdaq and on January 31, 2024, has received a 180 calendar day extension, until July 29, 2024, from Nasdaq to regain
compliance. Since then, Nasdaq staff has determined that for the last 10 consecutive business days, from July 12, 2024, to July 25, 2024, the closing bid price of the Company's Ordinary Shares has been at $1.00 per share or greater. Accordingly, the
Company has regained compliance with Listing Rule 5550(a)(2) and the matter has been closed.
|
• |
On July 30, 2024, the Company entered into an acknowledgment and payment schedule agreement with a third party regarding unpaid fees, charges, and
disbursements for services rendered to the Company. According to the terms of the agreement, the Company shall pay the sum of $54,000 on the first business day of each month for a period of twenty-four (24) months, with the first payment due
on November 1, 2024.
|
|
• |
On July 29, 2024, the Company announced that on July 26, 2024, it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating
that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement"). The Company is now in compliance with all applicable listing
standards and will continue to be listed and traded on the NASDAQ Stock Market.
|
| 2. |
Provide a general overview and discussion of the activities of management.
|
Management of the
Issuer (“Management”) is focused on continuing the Issuer’s growth in the cannabis markets in which it currently operates. Management is focused on managing its international assets and supply chain in order to maximize Issuer-wide revenue and
margins and continues to focus on its entry into the medical cannabis distribution and retail segments in Israel. Management also continues to identify and pursue new strategic investments and growth opportunities in Israel and Europe, including,
but not limited to, securing additional supply, distribution and sale agreements in Germany through Adjupharm GmbH and in Israel through its
subsidiaries and Focus Medical Herbs Ltd. (“Focus Medical”).
By exiting the
Canadian cannabis market, Management is seeking to focus its resources and maximize efficiency for future success. Management is reinforcing its Israeli and German operations and preparing to leverage its expertise into building market leadership
in the European medical cannabis market and to be fully ready
to capitalize on the recreational market upon legalization.
| 3. |
Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production
programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
|
In July 2024, the Issuer re-launched high THC premium cannabis strains in Israel called Pico
rainbow pie#8, CALIFORNIA. L, APPS& BANS, GLTO 33#, O.C, RAINBOW P.
| 4. |
Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production
programs that have been amended or abandoned.
|
Not Applicable.
| 5. |
Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services,
joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
|
Not Applicable.
| 6. |
Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing
arrangements that have been previously announced.
|
Not Applicable.
| 7. |
Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets
acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the
disposition was to a Related Person of the Issuer and provide details of the relationship.
|
Not Applicable.
| 8. |
Describe the acquisition of new customers or loss of customers.
|
Not Applicable.
| 9. |
Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software,
subscription lists and trade-marks.
|
Not Applicable.
| 10. |
Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
|
In July 2024, the Issuer hired 3 new employees and 2 resignations or terminations of employees occurred.
| 11. |
Report on any labour disputes and resolutions of those disputes if applicable.
|
Not applicable.
| 12. |
Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal
parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
|
Not applicable.
| 13. |
Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
|
Not Applicable.
| 14. |
Provide details of any securities issued and options or warrants granted.
|
Not Applicable.
| 15. |
Provide details of any loans to or by Related Persons.
|
Not Applicable.
| 16. |
Provide details of any changes in directors, officers or committee members.
|
Not Applicable.
| 17. |
Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.
|
Global economies are currently experiencing elevated levels of inflation, including in the
Issuer’s primary production markets, which could curtail levels of economic activity. Inflation concerns are in part driven by the increase in the cost of goods as input costs continue to increase due to several external factors, including but not
limited to, general uncertainties caused by the Ukraine war, the global supply chain constrictions and rising energy prices. As such, delivery and distribution costs, utility costs and other necessary supplies at an economic cost cannot be assured.
The impact of inflation and supply shortages on the integral components of the Issuer’s business could reasonably impact the Issuer’s future economic performance and competitiveness, as it may entail a meaningful increase in costs for various goods
and services that the Issuer may not be able to pass onto patients or customers. In addition, the Issuer’s operations could also be affected should interest rates, inflation or unemployment reach levels that change consumer trends and spending and
subsequently impact the sales and profitability of the Issuer.
The war in Ukraine may also have a material adverse effect on global economic activity and could
result in volatility and disruption to global supply chains and the financial and capital markets. These disruptions could cause interruptions in supplies and other services from third parties upon which the Issuer relies; decrease demand for
products; and cause staff shortages, reduced customer traffic and increased government regulation, all of which may materially and negatively impact the business, financial condition and results of operations of the Issuer, its subsidiaries and Focus
Medical.
As of February 2023, and to date, Israel is undergoing political and social instability relating
to the judicial and legislative reforms proposed by the newly elected government, creating certain instability and uncertainty. This instability which has a certain effect on the activity of the financial markets may cause material impact on the
Issuers’ ability to operate in the Israeli market.
On October 7, 2023, a war between the terror organization Hamas and Israel began. This war has an
impact on the company's business operations. The company has suffered a negative impact since its started and until this day, however, there might be a potential positive effect in the medium to long term. The company has experienced damages to its
ability to function, affecting various aspects, including employees, supplies, imports, sales, and more. While there are damages, it is still too early to fully assess the extent of their impact.
The Israeli ministry
of health announced the anticipated medical cannabis regulatory reform on August 7, 2023 (the "Reform"). The new regulations will remove many of the heavy regulations in the sector, making medical cannabis more accessible to patients as well as boosting export, all of which may
materially and positively impact the business, financial condition and results of operations of the Issuer, its subsidiaries and Focus Medical.
On December 8, 2023, the Issuer announced a 3-month delay of
the anticipated Reform that was originally scheduled for December 29, 2023, due to the Israel-Hamas war.
On April 1st, 224 the issuer announced that the Reform will be implemented in phases,
as approved and announced by the Israeli Ministry of Health. The key aspects of the initial phase, commencing April 1st, are as follows:
|
1. |
Change in the prescription process: patients with a wide range of diseases and medical conditions from Oncology to Parkinsons will no longer be
required to obtain a license to receive medical cannabis. Patients will receive a prescription similar to those for other prescription medications. Pain and PTSD are not included in the Reform yet.
|
|
2. |
Medical cannabis will now be prescribed through the HMO’s, Israel’s public healthcare system: until the Reform, cannabis could not be prescribed
through the HMO’s which cover the entire Israeli population.
|
|
3. |
The number of prescribing physicians will increase: as of today, HMO physicians, who are dully trained and certified within their field of expertise,
can prescribe medical cannabis as a first line treatment, as opposed to a last resort, based on medical discretion for the approved indications.
|
|
4. |
The cost for prescription will be reduced: the Ministry of Health limited the cost for a medical cannabis prescription.
|
"Anti-Dumping” investigation into cannabis imports from Canada
On January 18, 2024 , The Commissioner for Trade Levies at the Ministry of Economy and Industry,
announced by virtue of his authority according to Section 24(d) of the Law on Trade Levies and Defence Measures, 5591 – 1991, of his decision to open an investigation on his own initiative into the export import of cannabis from Canada, after he
found that special circumstances of actual damage exist or the probability of actual damage to the local manufacturing industry and a causal link between the imported imports and said damage.
The Ministry of Economy and Industry issued a formal notice to the public to respond to
questionnaires regarding the "Anti-Dumping" investigation.
The Issuer has submitted on March 10, 2024, the relevant questionnaires regarding Focus Medical
Herbal Ltd, IMC Pharma Ltd and Rosen High Way Ltd, it's related company and subsidiaries, respectively.
On June 18, 2024, the Ministry of Economy and Industry announced that it has decided to postpone
the final deadline for obtaining its preliminary decision until July 18, 2024.
On July 10th, 2024, the Commissioner published a preliminary decision regarding the
investigation and findings determining that there is dumping and consequent injury, on the basis of best information available. The Company is evaluating the preliminary decision and its potential impact on the Company and its subsidiaries. The
Company will submit its response by August 28, 2024, or by any extended deadline set by the Commissioner.
Germany - BfArM Regulation
The German Bundestag approved the federal government's draft law "on the controlled use of
cannabis" (BT Drs. 20/8704, BT Drs. 20/8763, BT-Drs. 20/10426) on Friday, 23 February 2024. The draft passed in the German Bundesrat on Friday, 22 March 2024, and essentially came into force on April 1, 2024 in accordance with Art. 15 of the draft.
Some components of Article 1 of the draft, which deals with so-called consumer cannabis, will not come into force until July 1, 2024 (according to Art. 15 para. 2 of the draft). This also has direct consequences for medicinal cannabis, which is the
subject matter of Art. 2 (Medical Cannabis Act - MedCanG) and 3 (BtMG) of the draft. With the entry into force of the draft law, cannabis is no longer a narcotic by definition and is therefore no longer subject to the BtMG. The change in regulation
has already led to rapid expansion within the first month, driven by the number of new patients entering into the market, highlighting the importance of a stable supply chain able to respond quickly to increases in demand.
The undersigned hereby certifies that:
| 1. |
The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this
Certificate of Compliance.
|
| 2. |
As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
|
| 3. |
The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in
National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
|
| 4. |
All of the information in this Form 7 Monthly Progress Report is true.
|
Dated: August 6, 2024
|
Oren Shuster |
|
|
Name of Director or Senior Officer
|
|
|
Chief Executive Officer |
|
|
Official Capacity |
|
|
Issuer Details
Name of Issuer
IM Cannabis Corp.
|
For Month End
July 2024
|
Date of Report
YY/MM/D
2024/8/6
|
|
Issuer Address
550 Burrard Street, Suite 2300, Bentall 5
|
|
City/Province/Postal Code
Vancouver, BC V6C 2B5
|
Issuer Fax No.
( )
|
Issuer Telephone No.
+972 542815033
|
|
Contact Name
Michal Lebovitz Nissimov
|
Contact Position
General Counsel
|
Contact Telephone No.
+972 542815033
|
|
Contact Email Address
Michal.l@imcannabis.com
|
Web Site Address
http://www.imcannabis.com/
|